NICE Decision On Arthritis Opens Door For Biosimilars
UK Recommends Treating Moderate Rheumatoid Arthritis With Three Biologic Molecules
A decision by the UK’s NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.
You may also be interested in...
In terms of broadening both access to treatment and stakeholder understanding, there remains plenty of room for growth for biosimilars in Europe, Medicines for Europe director general Adrian van den Hoven tells Generics Bulletin in an exclusive interview.
With the first approved rival to Lucentis in both the EU and US, Samsung Bioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.
Fresenius Kabi is continuing to suffer from the longstanding effects of the US FDA backlog for onsite inspection reviews amid the coronavirus pandemic. Management discussed Kabi’s latest prospects on its proposed pegfilgrastim biosimilar, as well as adalimumab and tocilizumab.